CXCL13 and rheumatoid arthritis: Both treatments resulted in decreased serum CXCL13 levels in patients with RA, but baminercept treatment was unable to diminish the serum levels of BAFF, LIGHT, or IP-10 compared to the placebo group (119, 120).